Exécution de notre outil de synthèse sur un nouvel article
Vérifiez l’article ci-dessous, puis lancez sa synthèse.
Targeting the tumor, harboring the host: IL-7 receptor-targeted CARs to treat T-ALL
Valeriya Kuznetsova (Memorial Sloan Kettering Cancer Center), Rishi K. Kothuru (Memorial Sloan Kettering Cancer Center), Prasad S. Adusumilli (Memorial Sloan Kettering Cancer Center), Alfredo Amador-Molina (Memorial Sloan Kettering Cancer Center)
Résumé : Chimeric antigen receptor (CAR) T cell therapy has fundamentally transformed clinical outcomes in B cell malignancies; however, the success story of CAR T cells has not yet extended to T cell acute lymphoblastic leukemia (T-ALL). A primary issue lies in the fundamental biology of the disease; most target antigens are shared between malignant T-ALL blasts and healthy T lymphocytes, including the CAR T cell product itself.